Article

Estrogen-induced contraction of coronary arteries is mediated by superoxide generated in vascular smooth muscle

Department of Pharmacology and Toxicology, Medical College of Georgia, 1120 15th St., Augusta, GA 30912-2300, USA.
AJP Heart and Circulatory Physiology (Impact Factor: 4.01). 11/2005; 289(4):H1468-75. DOI: 10.1152/ajpheart.01173.2004
Source: PubMed

ABSTRACT Although previous studies demonstrated beneficial effects of estrogen on cardiovascular function, the Women's Health Initiative has reported an increased incidence of coronary heart disease and stroke in postmenopausal women taking hormone replacement therapy. The objective of the present study was to identify a molecular mechanism whereby estrogen, a vasodilatory hormone, could possibly increase the risk of cardiovascular disease. Isometric contractile force recordings were performed on endothelium-denuded porcine coronary arteries, whereas molecular and fluorescence studies identified estrogen signaling molecules in coronary smooth muscle. Estrogen (1-1,000 nM) relaxed arteries in an endothelium-independent fashion; however, when arteries were pretreated with agents to uncouple nitric oxide (NO) production from NO synthase (NOS), estrogen contracted coronary arteries with an EC(50) of 7.3 +/- 4 nM. Estrogen-induced contraction was attenuated by reducing superoxide (O(2)(-)). Estrogen-stimulated O(2)(-) production was detected in NOS-uncoupled coronary myocytes. Interestingly, only the type 1 neuronal NOS isoform (nNOS) was detected in myocytes, making this protein a likely target mediating both estrogen-induced relaxation and contraction of endothelium-denuded coronary arteries. Estrogen-induced contraction was completely inhibited by 1 muM nifedipine or 10 muM indomethacin, indicating involvement of dihydropyridine-sensitive calcium channels and contractile prostaglandins. We propose that a single molecular mechanism can mediate the dual and opposite effect of estrogen on coronary arteries: by stimulating type 1 nNOS in coronary arteries, estrogen produces either vasodilation via NO or vasoconstriction via O(2)(-).

0 Followers
 · 
105 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coronary heart disease (CHD) continues to be the greatest mortality risk factor in the developed world. Estrogens are recognized to have great therapeutic potential to treat CHD and other cardiovascular diseases; however, a significant array of potentially debilitating side effects continues to limit their use. Moreover, recent clinical trials have indicated that long-term postmenopausal estrogen therapy may actually be detrimental to cardiovascular health. An exciting new development is the finding that the more recently discovered G-protein-coupled estrogen receptor (GPER) is expressed in coronary arteries-both in coronary endothelium and in smooth muscle within the vascular wall. Accumulating evidence indicates that GPER activation dilates coronary arteries and can also inhibit the proliferation and migration of coronary smooth muscle cells. Thus, selective GPER activation has the potential to increase coronary blood flow and possibly limit the debilitating consequences of coronary atherosclerotic disease. This review will highlight what is currently known regarding the impact of GPER activation on coronary arteries and the potential signaling mechanisms stimulated by GPER agonists in these vessels. A thorough understanding of GPER function in coronary arteries may promote the development of new therapies that would help alleviate CHD, while limiting the potentially dangerous side effects of estrogen therapy.
    World Journal of Cardiology (WJC) 06/2014; 6(6):367-75. DOI:10.4330/wjc.v6.i6.367 · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: (C, S, Sm)-tridoped mesoporous TiO2 is prepared by one-step hydrothermal method and characterized by X-ray diffraction (XRD), scanning electronic microscopy (SEM), X-ray photoelectron spectroscopy (XPS), Brunauer–Emmett–Teller (BET) method, UV–vis diffuse reflectance spectroscopy (DRS), and photoluminescence (PL) spectroscopy. By analyzing the structures and photocatalytic activities of (C, S, Sm)-tridoped TiO2 under visible light irradiation, the probable mechanism of tridoped TiO2 is investigated. It is assumed that the co-operation of nonmetal elements (C, S) and samarium not only leads to appreciable narrowing of the band gap, but also promotes the separation of the photo-generated electrons and holes, thus greatly improving the photocatalytic activity under visible light irradiation. The photocatalyst doped with C, S, and 1.0% Sm3+ shows the highest photocatalytic activity.
    Materials Chemistry and Physics 12/2010; 124(2):1210-1215. DOI:10.1016/j.matchemphys.2010.08.060 · 2.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Activation of GPER exerts a protective effect in hypertension and ischemia-reperfusion models. However, our understanding of the mechanisms of GPER-mediated vascular regulation is far from complete. In the current study, we tested the hypothesis that GPER-induced relaxation of porcine coronary arteries is mediated via cAMP/PKA signaling. Our findings revealed that vascular relaxation to the selective GPER agonist, G-1 (0.3-3 μM), was associated with increased cAMP production in a concentration-dependent manner. Furthermore, inhibition of adenylyl cyclase (AC) with SQ-22538 (100 μM) or inhibition of PKA activity with either Rp-8-CPT-cAMPS (5 μM ) or PKI (5 μM) attenuated G-1-induced relaxation of coronary arteries preconstricted with PGF2α 1 μM. G-1 also increased PKA activity in cultured coronary artery smooth muscle cells (SMC). We measured RhoA activity in cultured human and porcine coronary (SMC) and myosin light chain phosphatase (MLCP) activity in these artery rings by immunoblot analysis of phosphorylation of myosin-targeting subunit protein-1 (pMYPT-1, the MLCP regulatory subunit). G-1 decreased PGF2α induced pMYPT-1, while Rp-8-CPT-cAMPS prevented this inhibitory effect of G-1. Similarly, G-1 inhibited PGF2α-induced phosphorylation of MLC in coronary SMC, and this inhibitory effect was also reversed by Rp-8-CPT-cAMPS. RhoA activity was down regulated by G-1, whereas G36 (GPER antagonist) restored RhoA activity. Lastly, (100 µM) FMP-API-1, an inhibitor of the interaction between PKA and A kinase anchoring protein (AKAP), attenuated the effect of G-1 on coronary artery relaxation and pMYPT-1. These findings demonstrate that localized cAMP/PKA signaling is involved in GPER-mediated coronary vasodilation by activating MLCP via inhibition of RhoA pathway.
    AJP Endocrinology and Metabolism 07/2014; 307(4). DOI:10.1152/ajpendo.00534.2013 · 4.09 Impact Factor

Preview

Download
1 Download
Available from